Clinical Trials Logo

Clinical Trial Summary

To recognize predictors of left ventricular hypertrophy in hypertensive patients in Assiut government & to recognize the prognostic effect of central blood pressure measurement versus office brachial blood pressure measurement.


Clinical Trial Description

Many cohort studies have demonstrated that hypertension is a strong risk factor for total mortality and cardiovascular disease (CVD) in both developing and developed countries. Although brachial blood pressure (BP) mea¬surements have been used for over a century more and more data suggest that measuring of brachial BP has important limitations. First, a few office BP readings may not be representa¬tive of BP during a patient's daily life. Second, brachial BP may differ from systolic BP mea¬sured at the level of the ascending aorta, i.e. central BP, which is responsible for left ventri¬cle afterload and determines blood flow through coronary and brain arteries . Recent data from the Strong Heart Study confirm earlier results from smaller studies on high-risk patients that central pulse pressure is superior to brachial pulse pressure in the prediction of further cardiovascular events. The results of the Conduit Artery Function Evaluation (CAFE) study reminded clinicians of the importance of CBP. Those results demonstrated significant differences in CBP (central SBP and PP) between patient groups treated with different antihypertensive regimens even though peripheral BP levels were comparably lowered, and suggested the potential superiority of CBP to cuff brachial BP in cardiovascular prognostic predictive value in hypertensive patients. Modifiable risk factors for CVD that are common among adults with hypertension include cigarette smoking/tobacco smoke exposure, DM, dyslipidemia (including high levels of low-density lipoprotein cholesterol or hypercholesterolemia, high levels of triglycerides, and low levels of high-density lipoprotein cholesterol), overweight/obesity, physical inactivity/low fitness level, and unhealthy diet . There are clear examples around the world of ethnic variations in response to drug therapies epitomized by the benefits of thiazide diuretics and calcium channel blockers in lowering BP in blacks and perhaps in older people of all races, whereas blockers of the renin angiotensin system and β-adrenoceptor receptor blockers are just as effective in some other populations. Urbanization is a factor that profoundly affects BP patterns. In developed countries, hypertension is more common in rural populations than in urban. This pattern is reversed in developing, lower-, and middle-income countries where the first impact of rising rates of hypertension is seen in urban communities. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03482934
Study type Observational
Source Assiut University
Contact
Status Completed
Phase
Start date October 1, 2019
Completion date September 30, 2020

See also
  Status Clinical Trial Phase
Completed NCT02237339 - Does Allopurinol Reduce Thickening of the Left Ventricle of the Heart in Patient With Treated Hypertension? Phase 4
Completed NCT00041418 - Cardiac MR of Subclinical CVD: Impact of Age N/A
Completed NCT00005373 - Racial Differences in the Coronary Microcirculation N/A
Recruiting NCT00989508 - Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy Phase 2/Phase 3
Completed NCT03415750 - Everolimus and Tacrolimus Combination for Regression of Left Ventricular Hypertrophy in Renal Transplants Phase 4
Completed NCT02973607 - Effects of a Reduction in Renal Function on Cardiovascular Structure and Function
Completed NCT03749551 - Towards Understanding the Phenotype of Cardiovascular Disease in CKD - TRUE-Type-CKD Study
Completed NCT01976689 - New-onset Diabetes and Left Ventricular Hypertrophy in Renal Transplantation N/A
Enrolling by invitation NCT05713916 - Effect of a Targeted Notification and Clinical Support Pathway on Individuals With Left Ventricular Hypertrophy N/A
Recruiting NCT00552851 - Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant Phase 4
Active, not recruiting NCT03094143 - Early Valve Replacement Guided by Biomarkers of LV Decompensation in Asymptomatic Patients With Severe AS N/A
Completed NCT02444689 - EMPower: Electronic Media Powering Positive Health Changes in Youth N/A
Terminated NCT00616902 - The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5 Phase 3
Completed NCT00108082 - The CLEVER Study - Coreg And Left Ventricular Mass Regression Phase 3
Withdrawn NCT03315832 - Efficacy of Angiotensin Receptor Blocker Following aortIc Valve Intervention for Aortic STenOsis: a Randomized mulTi-cEntric Double-blind Phase II Study Phase 2/Phase 3
Completed NCT03180593 - Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH Phase 4
Completed NCT01144039 - Glutamate and Diastolic Function in Patients Undergoing Aortic Valve Repair Phase 4
Completed NCT00045994 - The SILVER Study: Systolic Hypertension Interaction With Left Ventricular Remodeling Phase 2
Active, not recruiting NCT02599480 - Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart Failure Phase 2
Active, not recruiting NCT04862273 - Native T1 CMR Imaging for Diagnosis of Cardiac Amyloidosis